在接种COVID-19疫苗后发生的血栓栓塞事件的最新情况
Theocharis Anastasiou1, Elias Sanidas1, Thekla Lytra2
1Department of Cardiology, "Laiko" General Hospital, 11527 Athens, Greece.
Vaccines
|August 28, 2025
概括
COVID-19 疫苗,特别是腺病毒载体类型,与罕见的血栓栓塞事件 (如 VITT) 有关. 然而,益处超过风险,mRNA疫苗的血栓发生率较低.
科学领域:
- 免疫学
- 疫苗学
- 血栓形成研究
背景情况:
- COVID-19 疫苗接种引发了有关血栓栓塞的担忧,尤其是腺病毒载体疫苗.
- 血栓塞栓并发症,包括VITT,ATE和VTE,很少发生,但疫苗接种后有记录.
研究的目的:
- 审查COVID-19疫苗接种后的血栓塞和并发症的发生和特征.
- 为了比较与不同疫苗平台相关的血栓风险.
- 强调目前的管理策略和COVID-19疫苗的整体效益风险概况.
主要方法:
- 关于COVID-19疫苗和血栓塞栓事件的文献综述.
- 对已报告的VITT,VTE,ATE和并发症的分析.
- 在腺病毒载体和mRNA疫苗之间对血栓形成风险的比较分析.
主要成果:
- 在接种COVID-19疫苗后发生的血栓栓塞事件 (VTE,ATE,VITT) 和罕见的并发症并不常见.
- 风险因素包括年龄,性别,疫苗类型和并发症.
- 与腺病毒载体疫苗相比,mRNA疫苗的严重血栓事件风险显著降低.
结论:
- 尽管有罕见的血栓并发症,但COVID-19疫苗对于预防严重疾病和死亡至关重要.
- 个性化风险评估和及时管理是关键.
- 由于血栓风险较低,mRNA疫苗是首选的.
相关概念视频
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Vaccinations
45.3K
Overview
45.3K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
Venous Thrombosis I: Introduction
40
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
40
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889


